{
    "clinical_study": {
        "@rank": "87377", 
        "arm_group": {
            "arm_group_label": "Diagnostic (7T ultra high-field MRI/MRS)", 
            "arm_group_type": "Experimental", 
            "description": "Patients undergo measurement of tumor perfusion and permeability using DCE-MRI, tumor cellularity using DW-MRI, phospholipid metabolism using 31P MRS, macromolecular content using MT-MRI, and cellular protein content using CEST-MRI. All of these procedures are integrated into a single MRI exam lasting under 60 min."
        }, 
        "brief_summary": {
            "textblock": "This pilot clinical trial studies ultra-high field magnetic resonance imaging (MRI) and\n      magnetic resonance spectroscopy (MRS) techniques in diagnosing breast cancer. New diagnostic\n      procedures may be a more sensitive way to detect breast cancer."
        }, 
        "brief_title": "Ultra High Field MRI and MRS Techniques in Diagnosing Breast Cancer", 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To implement quantitative dynamic contrast-enhanced (DCE)-MRI, diffusion-weighted\n      (DW)-MRI, 31 phosphorus (31P) MRS, magnetization transfer (MT)-MRI, chemical exchange\n      saturation transfer (CEST)-MRI, and high-resolution structural imaging at 7 Tesla in\n      patients for diagnosing breast tumors.\n\n      OUTLINE:\n\n      Patients undergo measurement of tumor perfusion and permeability using DCE-MRI, tumor\n      cellularity using DW-MRI, phospholipid metabolism using 31P MRS, macromolecular content\n      using MT-MRI, and cellular protein content using CEST-MRI. Diagnostic performance of one, or\n      a combination, of these metrics will be investigated in the context of breast cancer."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects must have signed an approved consent form\n\n          -  Must be at least 18 years old\n\n          -  Subjects must have undergone x-ray mammography and/or ultrasonography\n\n          -  Subjects must have undergone standard clinical (1.5 Tesla) MRI as part of their\n             standard-of-care diagnostic workup:\n\n               -  To evaluate the extent of disease for a previously diagnosed cancer, or\n\n               -  To evaluate a clinically suspected lesion that was occult on mammography and/or\n                  ultrasonography, or\n\n               -  Because the patient is considered high-risk (according to National Comprehensive\n                  Cancer Network [NCCN] criteria)\n\n          -  Subjects must be classified Breast Imaging-Reporting and Data System (BI-RADS) 4 or 5\n\n          -  Subjects must be scheduled for diagnostic biopsy to evaluate a lesion that measures\n             >10 mm in the greatest dimension.\n\n        Exclusion Criteria:\n\n          -  Subjects who have distant metastases\n\n          -  Subjects who have any type of bioimplant activated by mechanical, electronic, or\n             magnetic means (e.g., cochlear implants, pacemakers, neurostimulators,\n             biostimulators, electronic infusion pumps, aneurysm clip, etc), because such devices\n             may be displaced or malfunction\n\n          -  Subjects who have any type of ferromagnetic bioimplant that could potentially be\n             displaced by the magnetic field of the MRI scanner\n\n          -  Subjects who may have shrapnel imbedded in their bodies (such as from war wounds),\n             metal workers, and machinists (potential for metallic fragments in or near the eyes)\n\n          -  Subjects with a history of renal disease (including renal cancer), diabetes, or human\n             immunodeficiency virus (HIV)\n\n          -  Creatinine >= 1.5 times upper limit of normal\n\n          -  Estimated glomerular filtration rate < 30 mL/min\n\n          -  Subjects who are pregnant or breast-feeding; the MRI Procedure Screening Form will be\n             used to identify and exclude subjects who are pregnant or breastfeeding; a urine\n             pregnancy test/or serum human chorionic gonadotropin (HCG) will also be performed for\n             pre-menopausal women who are not using contraceptives\n\n          -  Subjects who have exhibited past allergic or other adverse reactions in response to\n             intravenous injection of Magnevist (gadopentetate dimeglumine) or other\n             gadolinium-containing contrast agents\n\n          -  Subjects who exhibit noticeable anxiety and/or claustrophobia or who exhibit severe\n             vertigo when they are moved into the magnet bore\n\n          -  Subjects incapable of giving informed written consent, for the following reasons:\n\n               -  Inability to adhere to the experimental protocols for any reason\n\n               -  Inability to communicate with the research team\n\n               -  Limited ability to give informed consent due to mental disability, altered\n                  mental status, confusion, or psychiatric disorders\n\n               -  Prisoners or other individuals deemed to be susceptible to coercion"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01938651", 
            "org_study_id": "VICC BRE 1277", 
            "secondary_id": "NCI-2013-00435"
        }, 
        "intervention": [
            {
                "arm_group_label": "Diagnostic (7T ultra high-field MRI/MRS)", 
                "description": "Undergo 7T MRI", 
                "intervention_name": "high field strength magnetic resonance imaging", 
                "intervention_type": "Procedure", 
                "other_name": "high field strength MRI"
            }, 
            {
                "arm_group_label": "Diagnostic (7T ultra high-field MRI/MRS)", 
                "description": "Undergo 31P MRS", 
                "intervention_name": "magnetic resonance spectroscopic imaging", 
                "intervention_type": "Procedure", 
                "other_name": [
                    "1H-nuclear magnetic resonance spectroscopic imaging", 
                    "Proton Magnetic Resonance Spectroscopic Imaging"
                ]
            }, 
            {
                "arm_group_label": "Diagnostic (7T ultra high-field MRI/MRS)", 
                "description": "Undergo CEST-MRI", 
                "intervention_name": "chemical exchange saturation transfer magnetic resonance imaging", 
                "intervention_type": "Procedure", 
                "other_name": "CEST MRI"
            }, 
            {
                "arm_group_label": "Diagnostic (7T ultra high-field MRI/MRS)", 
                "description": "Undergo DW-MRI", 
                "intervention_name": "diffusion-weighted magnetic resonance imaging", 
                "intervention_type": "Procedure", 
                "other_name": "diffusion-weighted MRI"
            }, 
            {
                "arm_group_label": "Diagnostic (7T ultra high-field MRI/MRS)", 
                "description": "Undergo DCE-MRI", 
                "intervention_name": "dynamic contrast-enhanced magnetic resonance imaging", 
                "intervention_type": "Procedure", 
                "other_name": "DCE-MRI"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 29, 2014", 
        "link": {
            "url": "http://www.vicc.org/ct/"
        }, 
        "location": {
            "contact": {
                "last_name": "Vanderbilt Cancer Center Clinical Trials Information Program", 
                "phone": "800-811-8480"
            }, 
            "facility": {
                "address": {
                    "city": "Nashville", 
                    "country": "United States", 
                    "state": "Tennessee", 
                    "zip": "37232"
                }, 
                "name": "Vanderbilt University Medical Center"
            }, 
            "investigator": {
                "last_name": "Thomas E. Yankeelov", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Ultra-High Field (7 Tesla) MRI/MRS Evaluation of Breast Cancer", 
        "overall_contact": {
            "last_name": "Vanderbilt Cancer Center Clinical Trials Information Program", 
            "phone": "800-811-8480"
        }, 
        "overall_official": {
            "affiliation": "Vanderbilt-Ingram Cancer Center", 
            "last_name": "Thomas Yankeelov", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Ninety-percent simultaneous confidence rectangles for sensitivity and specificity will be constructed at the 25th, 50th (median), and 75th percentiles of the model predicted probability of disease.", 
            "measure": "Sensitivity and specificity", 
            "safety_issue": "No", 
            "time_frame": "At time of imaging procedure"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01938651"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Vanderbilt-Ingram Cancer Center", 
            "investigator_full_name": "Thomas Yankeelov", 
            "investigator_title": "Director of Cancer Imaging Research, Vanderbilt University Institute of Imaging Science (VUIIS); Associate Professor of Radiology and Radiological Sciences, Biomedical Engineering, Physics and Astronomy, and Cancer Biology;", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "A generalized linear mixed models analysis of variance with a logit link will be used to predict pathological disease status from MRI and MRS parameters.", 
            "measure": "Pathological disease status", 
            "safety_issue": "No", 
            "time_frame": "At time of imaging procedure"
        }, 
        "source": "Vanderbilt-Ingram Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }, 
            "lead_sponsor": {
                "agency": "Vanderbilt-Ingram Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}